Charles Schwab Investment Management Inc. Raises Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA)

Charles Schwab Investment Management Inc. boosted its position in Sana Biotechnology, Inc. (NASDAQ:SANA) by 11.2% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 1,047,846 shares of the company’s stock after acquiring an additional 105,382 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Sana Biotechnology were worth $4,359,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SANA. Integral Health Asset Management LLC boosted its holdings in shares of Sana Biotechnology by 22.4% in the 2nd quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the company’s stock valued at $6,552,000 after purchasing an additional 220,000 shares during the last quarter. Algert Global LLC acquired a new position in Sana Biotechnology in the 2nd quarter worth $73,000. XTX Topco Ltd bought a new stake in shares of Sana Biotechnology in the 2nd quarter worth about $100,000. Bank of New York Mellon Corp increased its position in shares of Sana Biotechnology by 26.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 431,744 shares of the company’s stock worth $2,357,000 after purchasing an additional 90,423 shares during the last quarter. Finally, Dark Forest Capital Management LP grew its position in shares of Sana Biotechnology by 112.0% during the 2nd quarter. Dark Forest Capital Management LP now owns 27,314 shares of the company’s stock valued at $149,000 after buying an additional 14,430 shares during the last quarter. 88.23% of the stock is owned by hedge funds and other institutional investors.

Sana Biotechnology Stock Performance

Sana Biotechnology stock opened at $1.89 on Friday. The firm has a market cap of $421.98 million, a PE ratio of -1.35 and a beta of 1.33. The firm’s 50 day moving average price is $3.15 and its two-hundred day moving average price is $4.72. Sana Biotechnology, Inc. has a twelve month low of $1.81 and a twelve month high of $12.00.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.01. Equities analysts anticipate that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on SANA shares. HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Sana Biotechnology in a research report on Wednesday, November 27th. JMP Securities lowered shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th.

Insider Transactions at Sana Biotechnology

In related news, Director Richard Mulligan sold 150,000 shares of the company’s stock in a transaction on Tuesday, September 24th. The shares were sold at an average price of $4.08, for a total transaction of $612,000.00. Following the completion of the sale, the director now directly owns 2,848,121 shares of the company’s stock, valued at approximately $11,620,333.68. This represents a 5.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 31.10% of the stock is currently owned by company insiders.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.